The European Union is advancing its new pharmaceutical legislation, aiming to enhance competitiveness within the sector. This legislative effort comes in response to ongoing challenges faced by the pharmaceutical industry, including the need for innovation and streamlined regulatory processes. The proposed framework seeks to address these issues but has garnered a mixed reception from industry stakeholders.
Trade association EFPIA has expressed concerns, stating that the policies outlined in the new legislation are “not strong enough” to drive the necessary changes. This sentiment reflects a broader apprehension among pharma professionals regarding the adequacy of regulatory reforms to foster a more dynamic market environment. As the EU moves forward, the implications for regulatory, quality assurance, and supply chain operations could be significant, necessitating close attention from B2B professionals in the pharmaceutical sector.
Start your 7-day trial and see what the database can do →
